Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies
NI Mazur, MT Caballero, MC Nunes - The Lancet, 2024 - thelancet.com
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)
in young children is high. The RSV prevention strategies approved in 2023 will be essential …
in young children is high. The RSV prevention strategies approved in 2023 will be essential …
Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics
Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in
children under five years of age. Evidence-based management guidelines suggest that …
children under five years of age. Evidence-based management guidelines suggest that …
Eviction, health inequity, and the spread of COVID-19: housing policy as a primary pandemic mitigation strategy
The COVID-19 pandemic precipitated catastrophic job loss, unprecedented unemployment
rates, and severe economic hardship in renter households. As a result, housing precarity …
rates, and severe economic hardship in renter households. As a result, housing precarity …
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
C Rosas-Salazar, T Chirkova, T Gebretsadik… - The Lancet, 2023 - thelancet.com
Background Early-life severe respiratory syncytial virus (RSV) infection has been associated
with the onset of childhood wheezing illnesses. However, the relationship between RSV …
with the onset of childhood wheezing illnesses. However, the relationship between RSV …
Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis
Background With a suite of promising new RSV prophylactics on the horizon, including long-
acting monoclonal antibodies and new vaccines, it is likely that one or more of these will …
acting monoclonal antibodies and new vaccines, it is likely that one or more of these will …
[HTML][HTML] Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales
Abstract Introduction Respiratory Syncytial Virus (RSV) is a major cause of acute lower
respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one …
respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one …
Modeling respiratory syncytial virus adult vaccination in the United States with a dynamic transmission model
Background Respiratory syncytial virus (RSV) is shown to cause substantial morbidity,
hospitalization, and mortality in infants and older adults. Population-level modeling of RSV …
hospitalization, and mortality in infants and older adults. Population-level modeling of RSV …
[HTML][HTML] Determinants of RSV epidemiology following suppression through pandemic contact restrictions
Introduction COVID-19 related non-pharmaceutical interventions (NPIs) led to a suppression
of RSV circulation in winter 2020/21 in the UK and an off-season resurgence in Summer …
of RSV circulation in winter 2020/21 in the UK and an off-season resurgence in Summer …
Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life
AG Buchwald, BS Graham, A Traore… - Clinical Infectious …, 2021 - academic.oup.com
Background Respiratory syncytial virus (RSV) is a leading cause of viral pneumonia and
bronchiolitis during the first 6 months of life. Placentally transferred antibodies can prevent …
bronchiolitis during the first 6 months of life. Placentally transferred antibodies can prevent …
Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada
Background Despite passive immunization with palivizumab to select high-risk children
under two years of age, the health and economic burden of respiratory syncytial virus (RSV) …
under two years of age, the health and economic burden of respiratory syncytial virus (RSV) …